Rapid7, Inc. (RPD)

Rapid7: Q2 Beat Validates The Bull Case

Rapid7 Finds Nearly Two-Thirds of Vulnerabilities Exploited in Q2 2026 Required No User Interaction to Initiate

Is Rapid7 (RPD) a Great Value Stock Right Now?

Rapid7 Inc (RPD) Shares Fall 8.2% -- What GF Score of 59 Tells Investors

Rapid7-Omdia Research Reveals AI Governance Gap as Executive Security Leaders Show 1.6x Greater Concern Than Practitioners

Rapid7 Analysts Boost Their Forecasts Following Better-Than-Expected Q2 Earnings

Rapid7 Q2 Earnings Call Highlights

Rapid7 (RPD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Rapid7, Inc. (RPD) Q2 2026 Earnings Call Transcript

Rapid7 (RPD) Q2 Earnings and Revenues Top Estimates

Stay Ahead of the Game With Rapid7 (RPD) Q2 Earnings: Wall Street's Insights on Key Metrics

Rapid7 Becomes First Major Security Operations Platform to Unite SecOps and GRC

5 Takeover Targets for the AI Revolution

Rapid7 to Report Second Quarter 2026 Financial Results on August 10

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)

Rapid7 (RPD) Moves 7.6% Higher: Will This Strength Last?

Reveal Expands European Offerings with Private Deployment, AI-Powered Review and Logikcull's Government Transparency Solutions

Rapid7 Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Rapid7: New CEO And AI Opportunities Draw Attention